Casgevy Was Approved for Sickle Cell Disease. Getting Insurance to Cover It Is a Different Story.
Casgevy Was Approved for Sickle Cell Disease. Getting Insurance to Cover It Is a Different Story.
Casgevy Was Approved for Sickle Cell Disease. Getting Insurance to Cover It Is a Different Story.
7 minute read
In December 2023, the FDA approved Casgevy, known by its scientific name exagamglogene autotemcel, for the treatment of sickle cell disease and beta-thalassemia in patients 12 and older. It was a genuinely historic moment: the first CRISPR-based therapy ever approved by the FDA, developed by Vertex Pharmaceuticals and CRISPR Therapeutics.¹
For patients who have lived with sickle cell disease, a painful and often life-shortening inherited blood disorder, Casgevy represented something unprecedented: the possibility of a functional cure. Clinical trial data showed that 97 percent of patients treated with Casgevy experienced no severe vaso-occlusive crises for at least 12 months following treatment.¹
The list price set by Vertex and CRISPR Therapeutics is $2.2 million for a single treatment course.²
That number is not a typo. And it goes a long way toward explaining why, more than a year after approval, the number of patients who have actually received Casgevy remains very small, and why the barriers to access are substantial for many of the people it was designed to help.
What Casgevy Is and How It Works
Casgevy is a gene-editing therapy that uses CRISPR-Cas9 technology to modify a patient's own stem cells. The process involves collecting stem cells from the patient's blood, editing them in a laboratory to reduce the expression of a protein that drives sickling in red blood cells, and then infusing the edited cells back into the patient after a conditioning regimen.¹
The treatment is a one-time procedure, but it is not simple. It requires a highly specialized clinical site with a stem cell transplant program, a months-long process involving cell collection, laboratory editing, conditioning chemotherapy to prepare the body to accept the edited cells, and an inpatient hospital stay during infusion and early recovery.
Vertex has established a network of authorized treatment centers in the United States, most of which are major academic medical centers with bone marrow transplant capabilities.³ As of early 2025, there were approximately 50 authorized treatment centers in the United States, but access to these centers is geographically uneven.
The Coverage Picture One Year In
Getting coverage for Casgevy involves several distinct layers of barriers, and patients have encountered problems at nearly every one of them.
Prior authorization requirements. Because Casgevy is a specialty drug at an extraordinary price point, insurers require prior authorization. This is expected. What has made prior authorization for Casgevy particularly complicated is that clinical criteria are still evolving. Some insurers have developed specific PA criteria for gene therapies; others are applying criteria developed for more conventional hematology treatments that do not map cleanly onto a one-time curative therapy.
The Sickle Cell Disease Association of America and the Sickle Cell Warriors organization have documented cases where insurers requested documentation requirements that were difficult or impossible for patients to meet, including documentation of prior treatment failures with therapies that may not have been available or appropriate for the patient's specific case history.⁴
Site of care restrictions. Even when prior authorization is approved, some commercial plans have imposed site of care restrictions that limit where patients can receive the treatment. Because Casgevy must be administered at an authorized Vertex treatment center, a site of care restriction that directs patients to a non-authorized facility effectively blocks access entirely. Patients and advocates have had to navigate appeals specifically to establish that the treatment must be received at an authorized center.
Medicaid coverage gaps. Sickle cell disease disproportionately affects Black Americans, and a significant proportion of people with sickle cell disease are enrolled in Medicaid. Medicaid coverage of Casgevy has varied by state, and access through Medicaid has been slower to develop than commercial coverage. States must each make their own coverage decisions for drugs that do not have a federal mandate for coverage, and $2.2 million therapies create significant budget pressure for state Medicaid programs.
CMS has published guidance encouraging states to cover gene therapies through innovative payment models, including outcomes-based agreements and installment payment arrangements, which allow states to pay over time and link payments to whether the therapy works as expected.⁵ But as of early 2025, formal outcomes-based agreements for Casgevy had been established in only a limited number of states, leaving Medicaid coverage inconsistent nationally.
Commercial insurance lifetime dollar limits. While the Affordable Care Act prohibits annual and lifetime dollar limits on essential health benefits, the application of this prohibition to a $2.2 million one-time therapy has been tested in practice. Some patients have encountered insurers arguing that Casgevy does not meet specific coverage criteria or that it falls under carve-outs that affect how benefit limits apply.
What Vertex and CRISPR Therapeutics Offer
Vertex has established a patient support program that includes financial assistance for eligible patients, help with the prior authorization and appeals process, and coordination support for navigating the treatment center network.³ These programs are a meaningful resource, particularly for patients on commercial insurance who face cost-sharing amounts that would otherwise be unmanageable.
For patients whose insurers deny coverage, the manufacturer's patient support team can assist with documentation and appeals. This is not a guarantee of coverage, but having manufacturer support in an appeal can improve the quality of the clinical documentation package.
What You Can Do If You or Someone You Know Is Facing Coverage Barriers
If you or a family member has been prescribed Casgevy and encountered a denial or coverage barrier, the first step is to get the denial in writing with the specific reason stated. The denial notice must identify the clinical criteria used and the specific reason coverage was denied. That document is the foundation of your appeal.
Prior authorization denials for Casgevy are most often based on medical necessity criteria or site of care restrictions. An appeal should directly address the stated denial reason and include supporting documentation from your treating hematologist establishing the diagnosis, treatment history, and medical necessity for this specific therapy.
Patient advocacy organizations including the Sickle Cell Disease Association of America, the National Alliance of Sickle Cell Centers, and the Sickle Cell Warriors organization have experience supporting patients through coverage appeals and can connect you with resources specific to your state and insurer.⁴
For Medicaid patients in states that have not yet established formal coverage for Casgevy, a state Medicaid director exception or individual case review may be possible. Your hematologist's advocacy, combined with documentation from the authorized treatment center, is critical in those situations.
What This Means for You
Casgevy represents one of the most significant advances in sickle cell disease treatment in decades. The clinical results are compelling, and for patients who achieve remission from severe vaso-occlusive crises, the impact on quality of life and long-term health outcomes is meaningful.
But the reality of accessing a $2.2 million therapy in the current insurance landscape is complex, and the barriers are real. Prior authorization, site of care restrictions, and Medicaid coverage gaps are all obstacles that patients and families are navigating right now.
If you are working through a coverage denial for Casgevy or another high-cost specialty therapy, Ellen can help you understand your denial and build your appeal. Start here
Frequently Asked Questions
Is Casgevy covered by Medicare?
CMS has the authority to cover FDA-approved drugs and biologics under Medicare, and Casgevy is FDA-approved. Coverage under Medicare Part B (which covers many hospital-administered treatments) depends on whether the treatment is administered in a covered facility setting and meets Medicare's coverage criteria. Patients and their care teams should confirm Medicare coverage directly with their Medicare Administrative Contractor or through their treatment center's billing team.
What should I do if my insurer says Casgevy is experimental?
FDA approval means Casgevy is not experimental for the approved indications. Sickle cell disease and transfusion-dependent beta-thalassemia are the approved indications. If your insurer denies coverage calling the therapy experimental, your appeal should cite the FDA approval letter, the published clinical trial data, and any relevant clinical guidelines from the American Society of Hematology or other specialty organizations. An FDA-approved therapy cannot be denied solely on the basis that it is experimental.
Are there financial assistance programs available?
Vertex Pharmaceuticals offers a patient support program that includes assistance for eligible patients regardless of insurance status. The Sickle Cell Disease Association of America and other nonprofit organizations also provide navigation support and, in some cases, financial assistance resources. Contact Vertex's patient support line directly or ask your treatment center's financial counselor about available programs.
Sources: